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A B S T R A C T
Amphiphilic Janus-dendrimers are able to self-assemble into nanosized vesicles named dendrimersomes. We recently
synthesized the 3,5-C12-EG-(OH)4 dendrimer that generates dendrimersomes with very promising safety and stability
profiles, that can be loaded with different contrast agents for in vivo imaging. In this contribution, nanovesicles were
loaded with both the Magnetic Resonance Imaging (MRI) reporter GdDOTAGA(C18)2 and the glucocorticoid drug Pred-
nisolone Phosphate (PLP), in order to test their effective potential as theranostic nanocarriers on murine melanoma tu-
mour models. The incorporation of GdDOTAGA(C18)2 into the membrane resulted in dendrimersomes with a high longi-
tudinal relaxivity (r1 = 39.1 mM
− 1 s− 1, at 310 K and 40 MHz) so that, after intravenous administration, T1-weighted MRI
showed a consistent contrast enhancement in the tumour area. Furthermore, the nanovesicles encapsulated PLP with good
efficiency and displayed anti-tumour activity both in vitro and in vivo, thus enabling their practical use for biomedical
theranostic applications.
© 2016 Published by Elsevier Ltd.
1. Introduction
Despite the rapid advances in diagnostic and therapeutic protocols,
cancer still remains one of the most challenging domains of investiga-
tion in modern medicine. The limitations or the failure of current treat-
ments encouraged the research for innovative approaches to cancer
disease, in the effort to improve the early-stage detection and specifi-
cally target the therapy [1].
By combining both therapeutic and diagnostic properties in one
single platform, theranostic systems are emerging medical tools that
hold great promises in enhancing the therapeutic outcome of cancer
therapy [2–5]. Unlike conventional approaches, the theranostics in-
tegrates specific molecular targeting, therapeutic activity, and imag-
ing in one multifunctional medical system, very often based on the
use of nanosized carriers. Some of the most attractive features of the
nanoparticle-based theranostics include the opportunity to specifically
deliver different pharmaceutically active molecules, to monitor their
biodistribution in vivo, and, in some cases, also to control/trigger the
release of the drug at the target site [5,6].
So far, a very wide and continuously extending array of nanoplat-
forms has been considered for biomedical applications, but few of
them have received so much interest in the theranostic field as lipo-
somes. These vesicles, composed of a phospholipidic bilayer, already
proved their ability to load both imaging-responsive molecules and
drugs, and to act as theranostic agents in several pathologic scenarios,
especially in oncology [5,7].
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Following the work on liposomes, other nanosized bilayered vesic-
ular structures have been proposed. Among them, dendrimersomes
(DSs) are vesicles self-assembled from amphiphilic Janus-dendrimers,
described for the first time by Percec et al. in 2010 [8]. Based on
these initial studies, we argued whether DSs could be employed as
reliable alternative to liposomes in the advanced biomedical proto-
cols, especially considering the advantages in terms of cost and eas-
iness of synthesis of the dendrimeric constituents of the membrane.
Therefore, we initially evaluated the potential of these nanocarriers
to act as MRI agents by loading paramagnetic Gd-complexes either
in the aqueous core or in the membrane of the particles [9–11]. Fur-
thermore, we recently synthesized a new low generation Janus-den-
drimer (3,5-C12-EG-(OH)4, Chart 1, left) that has been demonstrated
to form Gd-loaded dendrimersomes of high stability and biocompati-
bility [10].
In this contribution, we report on the first in vivo testing of the
theranostic potential of DSs composed of the 3,5-C12-EG-(OH)4 den-
drimer, co-loaded with a drug (Prednisolone Phosphate, PLP, Chart 1)
and the lipophilic MRI agent GdDOTAGA(C18)2 (Chart 1), whose ex-
cellent MRI performance has been very recently demonstrated [11].
Since liposomal formulations of PLP already proved to be effective
in the treatment of melanoma [12–18], the herein investigated thera-
nostic platform was tested in vivo on a syngeneic murine melanoma
model and its therapeutic efficacy was compared to that provided by a
corresponding liposome-based formulation.
http://dx.doi.org/10.1016/j.jconrel.2017.01.010
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Chart 1. Structures of the dendrimersomes components. Left: 3,5-C12-EG-(OH)4 Janus dendrimer (main constituent of the dendrimersomes); middle: GdDOTAGA(C18)2 complex
(MRI agent incorporated in the dendrimersome bilayer); right: Prednisolone Phosphate (PLP, antitumour drug encapsulated in the inner core of the dendrimersomes).
2. Materials and methods
2.1. Chemicals
The phospholipids 1,2-distearoyl-sn-glycero-3 phospho-
ethanolamine-N-[carboxy(polyethyleneglycol)-2000] ammonium salt
(DSPE-PEG2000-COOH) and 1,2-dipalmitoyl-sn-glycero-3-phospho-
choline (DPPC) were purchased from Avanti Polar Lipids Inc. (Al-
abaster, AL, USA). The 3,5-C12-EG-(OH)4 Janus dendrimer was syn-
thesized as described elsewhere [10]. Briefly, the amphiphile was ob-
tained by linking the hydrophobic block 3,5 bis-dodecyl substituted
benzoyl ether to a generation 1 of 2,2-bis(hydroxymethyl)propanoic
acid, using ethylene glycol as spacer between the two moieties. The
first synthesis intermediate, a 2-hydroxyethyl 3,5-(didodecyloxy)ben-
zoate was obtained by reacting 3,5-(didodecyloxy)benzoic acid with
an excess of ethylene glycol in the presence of 4-(dimethylamino)pyri-
dinium p-toluenesulfonate (DPTS) and dicyclohexylcarbodiimide
(DCC). Following the same coupling procedure,
2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid was reacted with the
free hydroxyl group of the first synthesis intermediate. Deprotection
of the acetonide was carried out in a 1:1 mixture of 6 M HCl and THF
to get a generation zero intermediate. The final compound was ob-
tained by repeating once again the coupling and the deprotection steps.
GdDOTAGA(C18)2 was synthesized in a four steps-process start-
ing from the DOTAGA(tBu)4, as it was already reported in literature
[11]. Briefly, the free carboxylic acid of DOTAGA(tBu)4 was acti-
vated by formation of the N-hydroxysuccinimidyl ester, which was
then reacted with dioctadecylamine in pyridine at 70 °C. The free lig-
and was obtained after tBu esters deprotection using a 1:1 mixture of
TFA and dichloromethane and the Gd(III) complex was prepared by
reacting the ligand with GdCl3 in methanol at 50 °C overnight. All
other chemicals and reagents were purchased from Sigma-Aldrich (St.
Louis, USA), and used as received unless otherwise noted.
2.2. Nanovesicles preparation
DSs and liposomes were prepared by the thin film hydration
method [19]. Briefly, to prepare the stock samples with a concentra-
tion of 80 mg/ml in the final vesicle suspension useful to perform fur-
ther experiments, the appropriate amounts of amphiphilic materials
GdDOTAGA(C18)2, DSPE-PEG2000-COOH, and 3,5-C12-EG-(OH)4
dendrimer (or the phospholipid DPPC) were weighted according to
the molar ratio 20:5:75, and then dissolved into chloroform (8 ml).
After dissolution, the organic solvent was slowly evaporated, so that
the amphiphilic components distributed in a thin homogeneous film
at the bottom of a round flask. After 2 h under vacuum, the film was
hydrated at 50 °C with an isotonic buffered solution containing PLP
at 50 mg/ml, in addition to NaCl and 4-(2-hydroxyethyl)-1- piperazi-
neethanesulfonic acid (HEPES) with a final whole osmolarity of ca.
300 mOsm and pH of 7.4. The vesicular suspension was then extruded
several times through polycarbonate filters (Lipex extruder, Northern
Lipids Inc.) with pore diameters decreasing from 1 μm to 200 nm. Fi-
nally, to completely remove the non-encapsulated drug, an exhaustive
dialysis was carried out at 4 °C against an isotonic buffer consisting
of a pH 7.4 solution 0.15 M of NaCl and 0.004 of M 4-(2-hydrox-
yethyl)-1- piperazineethanesulfonic acid (HEPES), in a total volume
of 2 l and for a minimal duration of 16 h, with one buffer renewal after
the first 4 h.
2.3. Nanovesicles characterization
The mean hydrodynamic diameter and the polydispersity of the
vesicles were determined by Dynamic Light Scattering (DLS, Zeta-
sizer Nano 90 ZS, Malvern, UK).
The relaxometric characterization of GdDOTAGA(C18)2-bearing
nanoformulations was carried out to define the longitudinal relaxiv-
ity r1 (at 25 °C and 37 °C) as a function of the applied magnetic field.
Specific details about such measurements are available on the Elec-
tronic Supplementary Information (ESI). The total concentration of
Gd in the samples was determined by a relaxometric measurement (at
20 MHz) after mineralization. Briefly, the samples were diluted 1:2
with concentrated HCl (37%) and stored overnight at high tempera-
ture (120 °C) in a sealed glass ampoule to ensure the complete re-
lease of the metal ions from the complexes and to obtain free Gd(III)
aqua-ions. The R1
obs measurement (at 25 °C) allowed for the accurate
estimation of the Gd concentration through a calibration line obtained
by using standard solutions of GdCl3.
The total amount of PLP loaded into the vesicles was measured by
analytical high-performance liquid chromatography (HPLC), carried
out on a Waters Alliance System (separations module: 2695 model)
equipped with a photodiode array detector (model 2998) and a Wa-
ters Atlantis C18 reverse phase column (4.6 mm × 150 mm, 3.5 μm).
The chromatographic separation took 37 min in gradient mode, with
a re-equilibration time of 18 min to restore the initial conditions. Gra-
dient composition started from 95% of A (H2O containing 0.1% Tri-
fluoro Acetic Acid, TFA)-5% of B (CH3CN added with 0.1% TFA)
and it was maintained for 2.5 min. Then, B was raised to 30% at
15 min, 60% at 30 min, and finally 100% at 35 min remaining until
the end of the analysis. The total amount of PLP in the vesicular sus-
pension (5 mg of amphiphilic material per mL of hydration solution)
was quantified by monitoring the eluate through UV detection (de-
tection wavelengths set between 200 and 400 nm). The drug quantifi-
cation was performed at λ = 278 nm [20]. In order to determine the
drug-loading efficiency of the nanocarriers, the PLP content of sam-
ples was then compared to the initial amount of PLP present in the hy-
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2.4. Cells
All cell lines were obtained from American Type Culture Col-
lection (ATCC, Manassas, VA, USA) and resulted negative for my-
coplasma test (MycoAlert™ Mycoplasma Detection Kit, Lonza Sales
AG, Verviers, Belgium). Murine fibroblasts (NIH/3T3), melanoma
(B16.F10) and human umbilical vein endothelial (HUVEC) cells were
cultured as monolayers at 37 °C in a 5% CO2-containing humidified
atmosphere in Dulbecco's modified Eagle's medium (DMEM). The
medium was supplemented with 10% (v/v) of heat-inactivated foetal
bovine serum, 2 mM of Glutamine, 100 U/ml of penicillin and 100 μg/
ml of streptomycin. At 80% confluency, cells were trypsinized with
0.01% trypsin and 0.02% EDTA in Phosphate-buffered Saline (PBS).
All cells employed for cellular tests were at passages included be-
tween 5 and 10. Culture medium, fetal bovine serum, penicillin-strep-
tomycin mixture and trypsin were all purchased from Lonza (Lonza
Sales AG, Verviers, Belgium).
2.5. Cell viability assessment
Cell viability was assessed on murine fibroblasts (NIH/3T3),
melanoma (B16.F10) and human umbilical vein endothelial (HU-
VEC) cells after incubation with the paramagnetic dendrimersomes
(Gd-DS), PLP-loaded paramagnetic dendrimersomes (PLP-Gd-DS) or
liposomes (PLP-Gd-LIPO), and free PLP, after 1, 6 or 24 h incu-
bation. The selected doses of PLP and amphiphilic material were 1
and 40 mg/ml respectively, in all experiments. Before being added to
cell culture, vesicles or free PLP were diluted into culture medium to
achieve the desired concentration and filtered by sterile 0.4 μm filters.
The viability was assessed by a fluorimetric assay based on the cell
metabolic activity (CellTiter-Blue® Cell Viability assay, Promega,
Madison, USA). The CellTiter-Blue® reagent contains the indicator
dye Resazurin that is reduced to highly fluorescent Resofurin by vi-
able cells retaining metabolic capacities, so that the fluorescent sig-
nal generated from the assay is proportional to the number of liv-
ing cells in the sample. Briefly, NIH/3T3, HUVEC and B16.F10 cells
were plated in 96-well multiwell plate at a concentration of 1.0 × 104,
1.0 × 104 and 5.0 × 103 cells per well, respectively. After 24 h, cells
were exposed to the incubation medium for 1, 6 and 24 h. Next,
the incubation medium was removed and wells were washed three
times with sterile PBS (200 μl). The CellTiter-Blue® reagent was
added following manufacturer's instructions (20 μl of reagent diluted
1:5 into culture medium for each well). After 4 h, supernatants were
collected and placed in a black 96-well multiwell plate for fluores-
cence detection (excitation wavelength: 530–560 nm, emission wave-
length: 590 nm). Five independent experiments were performed to
test each single condition, with cells plated in triplicate and fluo
rescence measurements repeated three times. The reported results rep-
resent the mean ± SD of the percentage of viable cells, normalized
with respect to the control samples obtained by incubating cells with
PBS-containing medium.
2.6. Animals
Eight weeks old female C57/BL6 mice with similar weight (around
20–21 g) were used for the in vivo tests, with at least eight animals per
condition in all performed experiments. All mice involved in the study
were obtained from Charles River Laboratories (Calco, LC, Italy) and
maintained in standard housing conditions, with water and standard
rodent chow ad libitum and 12 h light/dark cycle. Animal manipula-
tion and all experimental procedures were performed in accordance
with the European Community guidelines and approved by the Italian
Ministry of Health.
2.7. In vivo MRI experiments
The performance of the theranostic probes was investigated in
mice bearing a syngeneic xenograft B16 melanoma tumour. Tumours
were generated by subcutaneous injection of 2.5 × 105 melanoma cells
(in 150 μl of PBS) on the flank of the animal. After 10 days, mice de-
veloped solid tumours of 2–4 mm in diameter, and were ready to begin
the treatment and the imaging procedures. For the MRI experiments,
mice were anesthetized by intramuscular injection of a combination of
tiletamine/zolazepam (zoletil 100; Virbac, Milan, Italy) 20 mg/kg and
xylazine (Rompum; Bayer, Milan, Italy) 5 mg/kg. Animals were ad-
ministered via tail vein injection with PLP-Gd-DS or PLP-Gd-LIPO,
receiving 0.04 mmol/kg of Gd(III) and 10 mg/kg of drug. Control ex-
periments were carried out by injecting the paramagnetic dendrimer-
somes (Gd-DS). As shown in Scheme 1, the administration was re-
peated twice over a time range of 2 weeks: at day 0 (corresponding to
the tenth day after tumour inoculation) and at day 7. MRI was carried
out immediately before, immediately after, and 1, 2, 4 and 6 days af-
ter each injection. An additional image acquisition was performed 6 h
after the second administration.
Images were acquired on a 1 T MRI Scanner (Aspect M2 High
Performance System, Aspect Magnet Technologies Ltd., Letanya, Is-
rael), consisting of NdFeB Magnet equipped with a solenoid Tx/Tr
coil of inner diameter of 35 mm. The system is equipped with a fast
gradient (gradient strength 450 mT m− 1 at 60 A, ramp time 250 μs at
160 μV), with a field homogeneity of 0.2–0.5 gauss. To evaluate the
imaging performance of DSs, T1-weighted images (T1w-images) were
acquired by using a standard spin echo sequence, setting the follow-
ing parameters: TR = 250 ms, TE = 8.9 ms, matrix size = 128 × 128,
slice thickness = 1.5 mm, NA = 8, FOV = 35 mm. The Mean Signal
Intensity (SI0) was calculated on T1w-images by manually drawing re
Scheme 1. Flowchart of the theranostic study. After tumour cells were subcutaneously inoculated, a time range of ten days was required for the tumour to develop. The nanoformu-
lations loaded with Gd-DOTAGA(C18)2 and PLP were injected at day 0 and day 7. MRI was carried out immediately before, immediately after and 24, 48, 96 and 144 h after each
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gions of interest (ROIs), and then it was normalized with respect to
the signal calculated on a glass tube containing 0.5 mM of Gadoteri-
dol in aqueous solution, that was used as an external reference during
image acquisition. The resulting value was the Normalized Signal In-
tensity, SIn. The T1 contrast enhancement (T1
Enh) was calculated from
the Normalized Signal Intensity values measured after the injection of
the theranostic agent (SIn
POST), after subtraction of the corresponding
value measured before the injection (SIn
PRE):
Multislice T2-weighted images were acquired by using a Fast Spin
Echo sequence set with the following parameters: TR = 2500 ms,
TE = 49.4 ms, matrix size = 160 × 152, slice thickness = 1.5 mm,
NA = 6, FOV = 40 mm. The tumour volume was determined by accu-
rately drawing a ROI along the perimeter of the lesion in each T2w-im-
age, and by simply adding all slice volumes. The tumour growth was
monitored for 15 days, and then the blood and the urine were sampled
immediately after the final MRI acquisition. Finally, the animals were
sacrificed and their organs (kidney, liver, spleen, muscle, heart, lung,
and tumour) were explanted. In a special cohort of animals (n = 8 per
condition), the sampling of blood and urine, and the organ explant
were performed on day 7, without providing the second administra-
tion of PLP-nanovesicles. The content of Gd(III) in the various tis-
sues was measured by the inductively coupled plasma mass spectrom-
etry (ICP-MS) after digestion. Briefly, the volume of blood and urine
samples and the weights of all organs were registered. Blood sam-
ples were added with heparin (20 μl) in order to avoid clotting and al-
low a precise quantification of the collected volume. Then, all biolog-
ical specimens were treated with concentrated HNO3 (70%) and di-
gested by applying microwave heating (Milestone MicroSYNTH, Mi-
crowave labstation equipped with an optical fiber temperature con-
trol and HPR-1000/6 M six position high-pressure reactor, Bergamo,
Italy). After digestion, the remaining material was diluted in ultra-
pure water (final volume of 3 mL) and further filtered with 0.2 μm fil-
ters. Finally, samples were analysed by ICP-MS (Thermo Scientific
ELEMENT 2 ICP-MS -Finnigan, Rodano, Milano, Italy). For urines,
the values of Gd(III) content were reported as metal concentration,
whereas for organs they were expressed with respect to the organ
mass. In case of blood, these values were finally reported as circulat-
ing metal concentration by calculating the Total Blood Volume (TBV)
for each animal from the average value reported for mice (79 ml/kg)
[20].
2.8. Statistical analysis
All data are presented as Mean Values ± Standard Deviation, un-
less noted otherwise. Significance of the differences among the ex-
perimental conditions was identified by applying the Student t-test or
ANOVA test, as indicated.
3. Results
3.1. In vitro characterization
By hydrating the amphiphilic films (GdDOTAGA(C18)2,
DSPE-PEG2000-COOH, and 3,5-C12-EG-(OH)4 in molar ratio
20:5:75) with an isotonic PLP-containing solution, vesicles with
favourable
physico-chemical properties for in vivo experiments were obtained.
The suspensions were found to show a good dimensional unifor-
mity (PDI values < 0.2) and a mean hydrodynamic diameter of around
150 nm (Table S1, ESI). As previously reported [10], the incorpora-
tion of the paramagnetic GdDOTAGA(C18)2 complex provided vesi-
cles with high proton relaxivity, achieving values of r1 around
39.1 mM− 1 s− 1 at 40 MHz and 310 K (Table S2 and Fig. S1, ESI).
Liposomes with a membrane composition analogue to DS in which
DPPS replaced the 3,5-C12-EG-(OH)4 dendrimer showed similar char-
acteristics, and were then chosen as control formulation in this study.
The two nanoformulations displayed a similar PLP loading efficiency
and were able to retain an almost equivalent fraction of PLP during
the preparation (0.34% and 0.29% of total PLP present in the suspen-
sions of DS and LIPO, respectively, when prepared at 5 mg/ml of am-
phiphilic materials).
3.2. Cytotoxicity
The potential capability of the theranostic dendrimersomes to hin-
der the cancer progression was tested in vitro on several cell cultures
(Fig. 1).
In order to assess either the direct anti-tumour or the anti-angio-
genic effects, melanoma cells (B16.F10 line, also used to generate the
in vivo model), and endothelial cells (HUVEC line) were incubated
with the control drug-free paramagnetic dendrimersomes (Gd-DS), the
paramagnetic PLP-loaded dendrimersomes (PLP-Gd-DS), the corre-
spondent liposomes (PLP-Gd-LIPO), and free PLP for 1, 6 or 24 h at
37 °C. A fibroblast cell line (NIH/3T3) was employed as a control to
identify possible unspecific cytotoxicity effects. In all conditions, the
incubation was carried out so as to always deliver the same dose of
PLP to the cells, and thereafter the cell viability was assessed. For all
cell lines, the addition of the simple paramagnetic dendrimersomes at
any incubation time range did not affect viability, thus indicating no
toxicity associated with the presence of the vehicle in the medium.
The free PLP dissolved into the medium induced only mild cytotox-
icity on control fibroblasts and melanoma cells, with slightly more
evident effects on melanoma cells at longer incubation times. How-
ever, the free PLP dramatically affected the endothelial cell viability,
which resulted severely impaired even at short incubation times (with
a decrease of 20.9% and 42.5% after 1 and 6 h, respectively). After
1 h of incubation with the PLP-loaded nanosystems, only limited ef-
fects were observed: the maximum viability reduction (≈ 8.6%) was
detected on endothelial cells after incubation with PLP-Gd-LIPO, but
all other data collected under these experimental conditions did not
substantially differ. After 6 h, the exposure to the nanosystems began
to induce a stronger cytotoxicity on HUVECs and, though to a mi-
nor extent, also on B16.F10 cells. Interestingly, in both cases a sta-
tistically relevant difference (p-value < 0.01 and 0.05 for endothelial
and melanoma cells, respectively) exists between the results obtained
with PLP-Gd-DS and PLP-Gd-LIPO, with the latter showing a slightly
higher effectiveness. Finally, for the longer incubation time (24 h),
the efficacy of the two nanomedicines was almost equivalent, even if
it varied depending on the tested cell line, being the endothelial and
melanoma cell viability reduced to 40% and 85%, respectively. Im-
portantly, in these conditions the treatment with the PLP-nanosystems
always matched the results observed with the use of free PLP. Finally,
it is arguable that some unspecific phenomena of cytotoxicity also oc-
curred, as shown by the decrease of the viable fibroblast number (10%
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Fig. 1. In vitro anti-tumour effects. Cell viability assessed by Resazurin/Resofurin assay on murine fibroblasts (NIH/3T3), melanoma (B16.F10) and human umbilical vein endothe-
lial (HUVEC) cells after treatment with empty paramagnetic dendrimersomes (Gd-DS), paramagnetic PLP-loaded dendrimersomes (PLP-Gd-DS) or liposomes (PLP-Gd-LIPO), and
free PLP. Incubation times were 1 h (a), 6 h (b) or 24 h (c). In all the experiments, the amounts of PLP and dendrimeric material were 1 mg/ml and 40 mg/ml, respectively. Statistical
significance addressed by ANOVA test (single and double asterisks indicating the p-value < 0.05 and 0.01, respectively).
3.3. In vivo MR imaging
In vivo 1 T MRI performed on melanoma-bearing mice after intra-
venous administration of PLP-Gd-DS revealed a consistent (ca. 50%)
contrast enhancement (T1
Enh) in the tumour area (Figs. 2 and 3) imme-
diately after the first injection (day 0).
As previously observed [10,14], the intratumour distribution of
the contrast-enhanced areas appeared inhomogeneous, possibly re-
flecting local differences in the vascularization, which could affect
the vesicular extravasation and the subsequent distribution of the con-
trast agents. After 24 h a similar T1
Enh value (51.2%) was still cal-
culated, whereas in the following days the contrast progressively de-
creased (T1
Enh ≈ 30.7% at day 7). After the second administration, the
T1
ENH values followed again a similar trend, remaining stable for about
24 h and then declining progressively. Also the control PLP-Gd-LIPO
displayed an equivalent ability to produce a positive signal in the tu-
mour without any relevant difference in the time evolution of the con-
trast. Moreover, whereas in the muscular tissue no remarkable con-
trast enhancement was detected, the spleen and the liver showed sub-
stantial T1
Enh values that persisted for several days after the injec
Fig. 2. T1 contrast enhancement (T1
Enh). Time evolution of the percentage T1 contrast enhancement (T1
ENH) calculated on T1w-images of tumour, muscle, liver and spleen after the
systemic administration of PLP-loaded dendrimersomes (black squares) and liposomes (gray circles) bearing the Gd-complex GdDOTAGA(C18)2. The time evolution of T1
ENH ob-
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Fig. 3. Representative MR images. Representative axial T1w-images showing the evo-
lution of T1 contrast over 15 days of MRI monitoring on liver (top), spleen (middle),
and tumour (bottom) after the administration of Gd-PLP-DS.
tion of both theranostic agents. This indicates the accumulation of
the nanosystems in the macrophage-rich organs of the mononuclear
phagocyte system (MPS). Furthermore, the imaging data obtained
with PLP-Gd-DS show a good accordance with previous studies,
where only a single administration of Gd-DS (0.05 mmol Gd/kg) was
performed [10]. Interestingly, after the second injection, the contrast
in the liver increased over time, similarly to what has been recently
reported in mice treated with liposomes loaded with Gadoteridol and
Doxorubicin [21]. Finally, the organs belonging to the excretory sys-
tem (kidneys and bladder, Fig. S2) were highlighted by a T1-contrast
increase only immediately after the injection (bolus passage), thus ex-
cluding the renal filtration of the paramagnetic probe and confirming
the good in vivo stability of the theranostic nanoparticles.
3.4. In vivo therapeutic effect
During the imaging sessions, anatomical T2w-images were also ac-
quired to assess the tumour volumes and monitor the disease progres-
sion (Fig. S3), thus enabling the evaluation of the effects of the drug
transported by the nanocarriers and their overall therapeutic validity
(Fig. 4). Both PLP-loaded dendrimersomes and liposomes were ca-
pable of delaying the tumour progression with respect to the case of
untreated animals. The two nanoformulations induced clear and sta-
tistically relevant therapeutic effects only by day 8 (Table S3), de-
termining a final decrease in the tumour growth rate of 39.1% and
32.4% for PLP-Gd-DS and PLP-Gd-LIPO respectively, at day 15. At
day 11 and 13, the increase in the tumour volume was slightly lower
in mice receiving PLP-Gd-DS than in those receiving PLP-Gd-LIPO
(p-value < 0.05), whereas at the previous time points and at day 15 no
substantial differences were detectable between the two groups.
3.5. Dendrimersome biodistribution
After the final MRI session (day 15), animals treated with
PLP-Gd-DS were sacrificed to quantify the residual amount of
Gadolinium in the different tissues (Fig. 5). Organs and tumours were
obtained also from a special additional cohort of diseased animals,
which were sacrificed at day 7 without receiving the second dose of
the theranostic dendrimersomes. As expected, a considerable metal
content was detected in the sites displaying the highest MRI contrast
(spleen, liver and tumour), whereas in the other investigated organs
(kidney, muscle, heart, and lung) the amount of Gd was negligible
both at day 7 and 15. On the one hand, the amount of Gd found in
liver and tumour at day 15 was approximately three times greater than
that measured at day 7; on the other hand, in the same time inter-
val the metal content in the spleen increased to a much lesser extent.
In the urine and blood collected immediately before the sacrifice, a
sub-micromolar amount of metal was detected, which almost doubled
from day 7 to day 15. By considering that the concentration of the
Fig. 4. Tumour growth and in vivo therapeutic effect. Time course of the tumour growth expressed as the percentage volume increase with respect to the initial tumour volume calcu-
lated at time 0 (20.4 ± 1.5 mm3), after the systemic administration of the control paramagnetic dendrimersomes (Gd-DS, white circles), the paramagnetic PLP-loaded dendrimersomes
(PLP-Gd-DS, black squares) or liposomes (PLP-Gd-LIPO, gray circles). Statistical significance addressed by ANOVA test (single and double asterisks indicating the p-value < 0.05
and 0.01, respectively).
Fig. 5. Residual gadolinium content in different tissues after the injection of PLP-Gd-DS. Amount of gadolinium normalized to the organ weight, measured by ICP-MS for different
organs (liver, spleen, kidney, lung, muscle, and tumour) excised from mice at day 7 before the second administration of theranostic vesicles (left) or at day 15 after the last MRI
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circulating Gd in a 19 g mouse at the moment of the first administra-
tion should approximately correspond to 506.7 μM under our experi-
mental conditions, one could estimate that after 7 days the metal con-
centration in blood is dramatically reduced by a factor of ca. 1700.
4. Discussion
Stimulated by the fact that dendrimersomes could represent a rel-
evant alternative to liposomes by virtue of the lower cost and the
easy synthetic approach of the starting materials [10], the aim of
the present study was to investigate the MRI theranostic potential of
drug-loaded DSs to treat cancer. The choice of the tumour model
and the therapeutic strategy relied on the previously reported ability
of liposomal PLP to inhibit the B16.F10 melanoma growth, possibly
through a series of distinct mechanisms of action [11–17]. The ex-
perimental conditions selected for the in vivo theranostic scheme, in-
cluding the time for initial tumour development (10 days) and that
dedicated to the MRI-monitoring (15 days), were defined on the ba-
sis of previous works [11,22] and pilot experiments carried out on
B16.F10-derived melanoma models. Although limited, a time window
of around 2 weeks already proved to be sufficient to monitor and as-
sess the therapeutic efficacy of PLP encapsulated in long-circulating
liposomes, showing that the tumour growth inhibition could be ob-
served after a single intravenous injection of 20 mg/kg/week in mice
bearing melanoma B16 or colon carcinoma C26 xenografts [23]. In
previous investigations, our group demonstrated the value of MRI in
monitoring the activity of paramagnetic liposomes for this type of ap-
plication, providing accuracy in the assessment of the therapeutic re-
sponse to melanoma cancer [22]. As a natural consequence, in this
study the results obtained for the DSs were compared to a standard
liposomal formulation endowed with similar physico-chemical char-
acteristics. Based on in vitro tests, liposomes and DSs share a simi-
lar ability to load the PLP during preparation, and when used on cell
lines they do not determine significantly different consequences on
the viability, except for a slight increase of the cytotoxicity observed
in case of the 6 h-long exposition to the liposome formulation. How-
ever, after one day of incubation this divergence vanished, so that
the effect produced by the two nanoformulations became again equiv-
alent and matched the cytotoxicity induced by the free PLP. Even
the in vivo performance of the two systems either in terms of imag-
ing contrast or therapeutic efficacy almost overlapped. Indeed, only
at late stages of the protocol (day 11 and 13) the PLP-Gd-DS effec-
tively provided some advantages in the anti-tumour efficacy as com-
pared to the PLP-Gd-LIPO, but at the end of the experimental mon-
itoring (day 15) such a difference turned out to be not statistical. Fi-
nally, the MRI contrast and the analytical quantification of gadolin-
ium suggest a long lasting residence of the DSs into the tumour tissue
and in the other accumulation sites commonly expected for nanopar-
ticles, as spleen and liver. Particularly, an accumulation phenome-
non was observed in the liver, possibly caused by the RES cell-me-
diated clearance of the nano-objects. This observation becomes more
interesting when considering that, due to a reduced ability in pro-
ducing pro-angiogenetic factors, the tumour-associated macrophages
(TAMs) were already defined as crucial players in the biological re-
sponse of B16.F10 melanoma to liposomal glucocorticoids [13]. It
has to be mentioned that the latest studies downgraded again the role
of TAMs, by underlying a broader spectrum of PLP activities which
includes also alterations of the tumour vasculature and dropdown of
the circulating white blood cells, probably limiting the infiltration of
angiogenesis-stimulating monocytes [16,17]. Nevertheless, based on
our results, the marked cytotoxic activity induced by the PLP-Gd-DS
and control liposomes on endothelial cells may support the previous
data identifying the inhibition of the angiogenetic process as one of the
leading therapeutic routes. Furthermore, the long-term retention of the
nanoprobes in the RES-organs may raise reasonable safety concerns
around the real biological applicability of this strategy, considering
the potential PLP-induced toxicity towards hepatic and splenic tissue.
In fact, even if rare, the occurrence of corticosteroid-induced acute
liver injury has been already described in the literature [24]. However,
since the liposomal encapsulation makes more effective the drug de-
livery, the PLP carried by nanovectors is generally administrated at
low dosages and well tolerated in vivo [12,25]. In our experimental
conditions, neither effects of acute toxicity were ever noticed on liv-
ing animals during the monitoring time, nor gross alterations (such
as infarct, necrosis, vacuolation) could be identified in the structure
or morphology of the organs by visual inspection after extraction for
the post-mortem Gd quantification. Moreover, the intravital destiny of
PLP after nanovectors-mediated uptake by the RES still has to be clar-
ified in order to understand if the long-term MRI signal in liver and
spleen could be ascribed to Gd-label deposition only [22], being thus
not indicative of the drug presence. This issue and the potential side
effects derived from non-specific PLP accumulation will be the ob-
jects for future research. Encouragingly in this perspective, a PLP li-
posomal formulation has been recently produced according to GMP
qualitative standards, and may be readily used in humans subjects, as
it turn out to be characterized by a very promising safety profile with
no specific evidence of PLP systemic accumulation [26].
5. Conclusions
In summary, the herein reported results indicate that
3,5-C12-EG-(OH)4 Janus dendrimers, loaded with a suitable para-
magnetic Gd(III) complex to ensure MRI detection, are capable of en-
capsulating PLP with efficiency and retention ability similar to con-
ventional liposomes. Importantly, also the anti-tumour activity and
the MR imaging performance of the dendrimersomes are quite com-
parable to those observed for the liposomal carrier. However, it is
important to highlight that DSs have some advantageous over lipo-
somes mainly related to the low cost and the easy synthetic approach
of the membrane constituents. In conclusion, the present report defin-
itively highlights the great potential of dendrimersomes as valuable
and cheaper alternative to liposomes for nanovesicles-based biomed-
ical applications.
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